(2)
Initial agreement provides up to 40 million doses to COVAX in 2021
First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure
For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price
NEW YORK CITY, NY and MAINZ, GERMANY,
January
, 2021 (GLOBE NEWSWIRE) - Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.
COVAX is a global initiative coordinated by the Global Alliance for Vaccines and Immunization (GAVI), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels. COVAX includes an Advanced Market Commitment (AMC) financial mechanism that aims
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat .
BioNTech SEJanuary 22, 2021 GMT
Initial agreement provides up to 40 million doses to COVAX in 2021
First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure
For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price
NEW YORK CITY, NY and MAINZ, GERMANY, January 22, 2021 (GLOBE NEWSWIRE) Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.
BioNTech SE
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
Initial agreement provides up to 40 million doses to COVAX in 2021
First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure
For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price
NEW YORK CITY, NY and MAINZ, GERMANY,
January
, 2021 (GLOBE NEWSWIRE) Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.
Date Time
Share
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price.
NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer and BioNTech SE today announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021.
COVAX is a global initiative coordinated by the Global Alliance for Vaccines and Immunization (GAVI), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels. COVAX includes an Advanced Market Commitment (AMC) financi
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that .
BioNTech SEJanuary 20, 2021 GMT
New York and Mainz, Germany, January 20, 2021 Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an
in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize the SARS-CoV-2 U.K. strain, also known as B.1.1.7 lineage or VOC 202012/01. The results were published on the preprint server bioRxiv and submitted to a peer-reviewed journal.